Xspray Pharma proposes a directed issue of 1,350,000 shares corresponding to approximately SEK 88 million to expand the product portfolio
The board of directors of Xspray Pharma AB (publ) has resolved to propose a directed share issue of 1,350,000 shares at a subscription price of SEK 65 per share, representing a discount of 2 percent compared to the volume weighted average price during the last five trading days. The share issue will provide Xspray Pharma with approximately SEK 88 million before transaction costs. The objective of the proposal and the reasons for the deviation from the shareholders’ preferential rights are to strengthen the institutional shareholder base in the company and in a timely manner enable the